C McDanal

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression

A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago

The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1

Herpesvirus Saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.